Challenges in the treatment of infections caused by gram-positive and gram-negative bacteria in patients with cancer and neutropenia

Clinical Infectious Diseases

Volumn 40, Issue SUPPL. 4, 2005, Pages

  Rolston, Kenneth V I ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE; ANTIBIOTIC AGENT; BETA LACTAMASE AMPC; CARBAPENEM; CEFTAZIDIME; CEPHALOSPORIN; CIPROFLOXACIN; COLISTIN; LIPOPEPTIDE; NORFLOXACIN; OFLOXACIN; OXAZOLIDINONE DERIVATIVE; PIPERACILLIN PLUS TAZOBACTAM; POLYMYXIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; BACTERIAL INFECTION; CHEMOTHERAPY; FEBRILE NEUTROPENIA; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HIGH RISK PATIENT; HUMAN; INFECTION RESISTANCE; INFECTION RISK; INFECTION SENSITIVITY; MULTIDRUG RESISTANCE; MYCOSIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT;

AMBULATORY CARE; ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, BACTERIAL; GRAM-NEGATIVE BACTERIAL INFECTIONS; GRAM-POSITIVE BACTERIAL INFECTIONS; HOSPITALIZATION; HUMANS; IMMUNOCOMPROMISED HOST; NEOPLASMS; NEUTROPENIA; OPPORTUNISTIC INFECTIONS; RISK ASSESSMENT;

EID: 15744391244     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/427331     Document Type: Review

References (60)

1. Bodey GP. Infection in cancer patients: a continuing association. Am J Med 1986; 81(Suppl 1A):11-26.
2. Hughes WT, Armstrong D, Bodey GP, et al. 2002 Guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002; 34:730-51.
3. Rolston KVI, Bodey GP. Infections in patients with cancer. In: Kufe DW, Pollock RE, Weichselbaum RR, et al., eds. Holland-Frei cancer medicine. Hamilton and London, Ontario: B. C. Decker, 2003:2633-58.
4. Bodey GP, Ho DH, Elting L. Survey of antibiotic susceptibility among gram-negative bacilli at a cancer hospital. Am J Med 1988; 85(Suppl 1A):49-51.
5. Rolston KVI, Elting L, Waguespack S, Ho DH, LeBlanc B, Bodey GP. Survey of antibiotic susceptibility among gram-negative bacilli at a cancer center. Chemotherapy 1996; 42:348-53.
6. Jacobson K, Rolston K, Elting L, LeBlanc B, Whimbey E, Ho DH. Susceptibility surveillance among gram-negative bacilli at a cancer center. Chemotherapy 1999; 45:325-34.
7. Jones RN. Contemporary antimicrobial susceptibility patterns of bacterial pathogens commonly associated with febrile patients with neutropenia. Clin Infect Dis 1999; 29:495-502.
8. Rolston KVI, Kontoyiannis DP, Raad II, et al. Susceptibility surveillance among gram-negative bacilli at a comprehensive cancer center [abstract A-004]. In: Program and abstracts of the 103rd General Meeting of the American Society for Microbiology (Washington, DC). Washington, DC: American Society for Microbiology, 2003:1.
9. Pizzo PA. Management of fever in patients with cancer and treatment-induced neutropenia. N Engl J Med 1993; 328:1323-32.
10. Rolston KVI, Tarrand JJ. Pseudomonas aeruginosa - still a frequent pathogen in patients with cancer: 11-year experience at a comprehensive cancer center. Clin Infect Dis 1999; 29:463-4.
11. Bodey GP, Jadeja L, Elting L. Pseudomonas bacteremia: retrospective analysis of 410 episodes. Arch Intern Med 1985; 145:1621-9.
12. Chatzinikolaou I, Abi-Said D, Bodey GP, Rolston KV, Tarrand JJ, Samonis G. Recent experience with Pseudomonas aeruginosa bacteremia in patients with cancer: retrospective analysis of 245 episodes. Arch Intern Med 2000; 160:501-9.
13. Zinner SH. Changing epidemiology of infections in patients with neutropenia and cancer: emphasis on gram-positive and resistant bacteria. Clin Infect Dis 1999; 29:490-4.
14. Wisplinghoff H, Seifert H, Wenzel RP, Edmond MB. Current trends in the epidemiology of nosocomial bloodstream infections in patients with hematological malignancies and solid neoplasms in hospitals in the United States. Clin Infect Dis 2003; 36:1103-10.
15. Yadegarynia D, Tarrand J, Raad I, Rolston K. Current spectrum of bacterial infections in patients with cancer. Clin Infect Dis 2003; 37:1144-5.
16. Adachi JA, Yadegarynia D, Rolston K. Spectrum of polymicrobial bacterial infection in patients with cancer, 1975-2002 [abstract 4]. In: Program and abstracts of the 103rd General Meeting of the American Society for Microbiology (polymicrobial diseases) (Lake Tahoe, NV). Washington, DC: American Society for Microbiology, 2003:20.
17. Elting LS, Bodey GP, Fainstein V. Polymicrobial septicemia in the cancer patient. Medicine (Baltimore) 1986; 65:218-25.
18. National Nosocomial Infections Surveillance (NNIS) System Report. Data summary from January 1992-June 2001. Issued August 2001. Am J Infect Control 2001; 29:404-21.
19. Diekema DJ, Coffman SL, Marshall SA, Beach ML, Rolston KV, Jones RN. Comparison of activities of broad-spectrum β-lactam compounds against 1,128 gram-positive cocci recently isolated in cancer treatment centers. Antimicrob Agents Chemother 1999; 43:940-3.
20. Diekema DJ, Jones RN, Rolston KVI. Antimicrobial activity of gati-floxacin compared to seven other compounds tested against gram-positive organisms isolated at 10 cancer-treatment centers. Diagn Microbiol Infect Dis 1999; 34:37-43.
21. Matar MJ, Tarrand J, Raad II, et al. Vancomycin-resistant enterococci (VRE) in cancer patients: rates of colonization, infections sites, species differentiation and antibiotic susceptibilities [abstract 59]. In: Program and abstracts of the 39th Annual Meeting of the Infectious Diseases Society of America (San Francisco). Alexandria, VA: Infectious Diseases Society of America, 2001:49.
22. Rolston KVI, Raad II. In vitro activity of quinolones against viridans streptococci isolated from cancer patients [abstract E-155]. In: Program and abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago). Washington, DC: American Society for Microbiology, 2003:201.
23. Jones RN, Pfaller MA. Potencies of newer fluoroquinolones against viridans group streptococci isolated in 637 cases of bloodstream infection in the SENTRY Antimicrobial Surveillance Program (1997 to 1999): beyond Canada! Antimicrob Agents Chemother 2000; 44:2922-3.
24. Tunkel AR, Sepkowitz KA. Infections caused by viridans streptococci in patients with neutropenia. Clin Infect Dis 2002; 34:1524-9.
25. Safdar A, Rolston KVI. Vancomycin-tolerant non-enterococcal gram-positive bacteremia: an emerging phenomenon in patients with cancer [abstract 65]. In: Program and abstracts of the 13th International Symposium on Infections in the Immunocompromised Host (Granada, Spain). Suwanee, GA: International Immunocompromised Host Society, 2004:18.
26. Carratala J, Fernandez-Sevilla A, Tubau F, Callis M, Gudiol F. Emergence of quinolone-resistant Escherichia coli bacteremia in neutropenic patients with cancer who have received prophylactic norfloxacin. Clin Infect Dis 1995; 20:557-60; discussion 561-3.
27. Kern WV, Andriof E, Oethinger M, Kern P, Hacker J, Marre R. Emergence of fluoroquinolone-resistant Escherichia coli at a cancer center. Antimicrob Agents Chemother 1994; 38:681-7.
28. Rolston KVI. Commentary: chemoprophylaxis and bacterial resistance in neutropenic patients. Infect Dis Clin Pract 1998; 7:202-4.
29. Rolston KVI, Kontoyiannis DP, Raad II. In vitro activity of newer quinolones against non-fermentative gram-negative bacilli (NFGNB) isolated from cancer patients [abstract E-148]. In: Program and abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago). Washington, DC: American Society for Microbiology, 2003:199.
30. Paterson DL, Rice LB. Empirical antibiotic choice for the seriously ill patient: are minimization of selection of resistant organisms and maximization of individual outcome mutually exclusive? Clin Infect Dis 2003; 36:1006-12.
31. Bradford PA. Extended-spectrum β-lactamases in the 21st century, characterization, epidemiology, and detection of this important resistance threat. Clin Microbiol Rev 2001; 14:933-51
32. Babini GS, Livermore DM. Antimicrobial resistance amongst Klebsiella spp. collected from intensive care units in Southern and Western Europe in 1997-1998. J Antimicrob Chemother 2000; 45:183-9.
33. Odeh R, Kelkar S, Hujer AM, Bonomo RA, Schreckenberger PC, Quinn JP. Broad resistance due to plasmid-mediated AmpC β-lactamases in clinical isolates of Escherichia coli. Clin Infect Dis 2002; 35:140-5.
34. Toleman MA, Rolston K, Jones RN, Walsh TR. Molecular and biochemical characterization of OXA-45, an extended-spectrum class 2d′ β-lactamase in Pseudomonas aeruginosa. Antimicrob Agents Chemother 2003; 47:2859-63.
35. VIM-7, an evolutionarily distinct metallo-β-lactamase gene in a Pseudomonas aeruginosa isolate from the United States. Antimicrob Agents Chemother 2004; 48:329-32.
36. Nguyen KA, Coyle EA, Tam VH, et al. Antibacterial activity of colistin (C) and polymyxin B (PB) against multidrug-resistant (MDR) Pseudomonas aeruginosa (PSA), Alcaligenes xylosoxidans (AX), and Stenotrophomonas maltophilia (SM) at a cancer center [abstract E-2039]. In: Program and abstracts of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy (Washington, DC). Washington, DC: American Society for Microbiology, 2004:182.
37. Whitecar JP Jr, Luna M, Bodey GP. Pseudomonas bacteremia in patients with malignant diseases. Am J Med Sci 1970; 60:216-23.
38. Bodey GP. Antibiotics in patients with neutropenia. Arch Intern Med 1984; 144:1845-51.
39. Saurina G, Quale JM, Manikal VM, Oydna E, Landman D. Antimicrobial resistance in Enterobacteriaceae in Brooklyn, NY: epidemiology and relation to antibiotic usage patterns. J Antimicrob Chemother 2000; 45:895-8.
40. Rahal JJ, Urban C, Horn D, et al. Class restriction of cephalosporin use to control total cephalosporin resistance in nosocomial Klebsiella. JAMA 1998; 280:1233-7.
41. Donskey CJ, Schreiber JR, Jacobs MR, et al. A polyclonal outbreak of predominantly VanB vancomycin-resistant enterococci in northeast Ohio. Northeast Ohio Vancomycin-Resistant Enterococcus Surveillance Program. Clin Infect Dis 1999; 29:573-9.
42. Gerding DN, Larson TA. Aminoglycoside resistance in gram-negative bacilli during increased amikacin use: comparison of experience in 14 United States hospitals with experience in the Minneapolis Veterans Administration Medical Center. Am J Med 1985; 79:1-7.
43. Raymond DP, Pelletier SJ, Crabtree TD, et al. Impact of a rotating empiric antibiotic schedule on infectious mortality in an intensive care unit. Crit Care Med 2001; 29:1101-8.
44. Finberg RW, Moellering RC, Tally FP, et al. The importance of bactericidal drugs: future directions in infectious diseases. Clin Infect Dis 2004; 39:1314-20.
45. Sculier JP, Klastersky J. Significance of serum bactericidal activity in gram-negative bacillary bacteremia in patients with and without granulocytopenia. Am J Med 1984; 76:429-35.
46. Craig WA. Once-daily versus multiple-daily dosing of aminoglycosides. J Chemother 1995; 7:47-52.
47. Turnidge JD. The pharmacodynamics of β-lactams. Clin Infect Dis 1998; 27:10-22.
48. Rolston KVI. New trends in patient management: risk-based therapy for febrile patients with neutropenia. Clin Infect Dis 1999; 29:515-21.
49. Talcott JA, Siegel RD, Finberg R, Goldman L. Risk assessment in cancer patients with fever and neutropenia: a prospective, two-center validation of a prediction rule. J Clin Oncol 1992; 10:310-22.
50. Klastersky J, Paesmans M, Rubenstein EB, et al. The Multinational Association for Supportive Care in Cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 2000; 18:3038-51.
51. Freifeld A, Marchigiani D, Walsh T, et al. A double-blind comparison of empirical oral and intravenous antibiotic therapy for low-risk febrile patients with neutropenia during cancer chemotherapy. N Engl J Med 1999; 341:305-11.
52. Kern WV, Cometta A, De Bock R, Langenaeken J, Paesmans M, Gaya H. Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy. International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. N Engl J Med 1999; 341:312-8.
53. Talcott JA, Whalen A, Clark J, Rieker PP, Finberg R. Home antibiotic therapy for low-risk cancer patients with fever and neutropenia: a pilot study of 30 patients based on a validated prediction rule. J Clin Oncol 1994; 12:107-14.
54. Malik IA, Khan WA, Karim M, Aziz Z, Khan MA. Feasibility of outpatient management of fever in cancer patients with low-risk neutropenia: results of a prospective randomized trial. Am J Med 1995; 98:224-31.
55. Gardembas-Pain M, Desablens B, Sensebe L, Lamy T, Ghandour C, Boasson M. Home treatment of febrile neutropenia: an empirical oral antibiotic regimen. Ann Oncol 1991; 2:485-7.
56. Rubenstein EB, Rolston K, Benjamin RS, et al. Outpatient treatment of febrile episodes in low-risk neutropenic patients with cancer. Cancer 1993; 71:3640-6.
57. Mullen CA, Petropoulos D, Roberts WM, et al. Outpatient treatment of fever and neutropenia for low risk pediatric cancer patients. Cancer 1999; 86:126-34.
58. Hidalgo M, Hornedo J, Lumbreras C, et al. Outpatient therapy with oral ofloxacin for patients with low risk neutropenia and fever: a prospective, randomized clinical trial. Cancer 1999; 85:213-9.
59. Rolston KV. Prediction of neutropenia. Int J Antimicrob Agents 2000; 16:113-5.
60. Spellberg B, Powers JH, Brass EP, Miller LG, Edwards JE Jr. Trends in antimicrobial drug development: implications for the future. Clin Infect Dis 2004; 38:1279-86.